NewAmsterdam Pharma Company NV - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NAMS Nasdaq 2836 https://www.frazierlifesciencesacquisition.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NewAmsterdam Pharma Company NV

NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference - Mar 1st, 2023 1:00 pm
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference - Feb 9th, 2023 1:00 pm
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors - Feb 6th, 2023 1:00 pm
NewAmsterdam Pharma (NASDAQ:NAMS) delivers shareholders 15% return over 1 year, surging 17% in the last week alone - Jan 26th, 2023 10:50 am
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy - Jan 17th, 2023 1:00 pm
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer - Dec 19th, 2022 9:01 pm
VectivBio Announces Results of Extraordinary General Meeting - Dec 9th, 2022 9:01 pm
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients - Nov 23rd, 2022 1:00 pm